Shionogi & Co EBIT per Share
The EBIT per Share of Shionogi & Co (4507.T) as of Oct 14, 2026 is 189.60 JPY. In the previous year, EBIT per Share was 187.73 JPY — a change of 0.99% (higher).
Get this data via API
Financial Data API
EBIT per Share
189.60JPY
YoY
0.99%
Last updated:
EBIT per Share of Shionogi & Co is 2026 189.60 JPY. EBIT per Share of Shionogi & Co was 2025 187.73 JPY. It decreases by 0.99% higher compared to the previous year.
The Shionogi & Co EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2024
201.51 JPY
Jan 1, 2025
187.73 JPY
Jan 1, 2026
189.60 JPY
Jan 1, 2027 (e)
302.31 JPY
Jan 1, 2028 (e)
333.21 JPY
Jan 1, 2029 (e)
336.15 JPY
Jan 1, 2030 (e)
329.47 JPY
Jan 1, 2031 (e)
224.64 JPY
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 224.64JPY | -31.82% |
| est | 329.47JPY | -1.99% |
| est | 336.15JPY | +0.88% |
| est | 333.21JPY | +10.22% |
| est | 302.31JPY | +59.44% |
| 189.60JPY | +0.99% | |
| 187.73JPY | -6.84% | |
| 201.51JPY | +8.69% | |
| 185.39JPY | +47.43% | |
| 125.75JPY | +19.39% | |
| 105.33JPY | -25.17% | |
| 140.75JPY | -5.98% | |
| 149.70JPY | +22.53% | |
| 122.18JPY | +8.01% | |
| 113.11JPY | +20.88% | |
| 93.58JPY | +81.49% | |
| 51.56JPY | -18.49% | |
| 63.26JPY | +8.00% | |
| 58.57JPY | +25.20% | |
| 46.78JPY | +0.24% | |
| 46.67JPY | -10.58% | |
| 52.19JPY | +63.80% | |
| 31.86JPY | -20.75% | |
| 40.20JPY | +18.56% | |
| 33.91JPY | — |
Access this data via the Eulerpool API
Shionogi & Co Stock analysis
What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange.
Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections.
In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA.
Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base.
In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication.
Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases.
Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Shionogi & Co stock
EBIT per Share of Shionogi & Co is 189.60 JPY in 2026.
EBIT per Share of Shionogi & Co changed from 187.73 JPY to 189.60 JPY, representing a 0.99% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Shionogi & Co
All Key Metrics — Shionogi & Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth